Theravance Biopharma to Join May 2024 Investor Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) is slated to engage in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST). In addition to the chat, the company will also host in-person meetings with the investment community during the event.

For those who cannot attend in person, a webcast of the Fireside Chat will be accessible via Theravance's official website. Interested parties can navigate to the Investors section under Events and Presentations to view the live stream. The webcast replay will remain available on the company's site for a period of 30 days following the event.

Theravance Biopharma, Inc. is dedicated to delivering transformative medicines that significantly impact patients' lives. The company's portfolio includes YUPELRI® (revefenacin) inhalation solution, an FDA-approved medication designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Another promising product in their pipeline is Ampreloxetine, a late-stage investigational drug. Ampreloxetine is a norepinephrine reuptake inhibitor that is being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). This drug holds the potential to be a pioneering therapy, effectively addressing a range of key symptoms experienced by MSA patients.

Theravance Biopharma is steadfast in its mission to enhance shareholder value while advancing innovative healthcare solutions. The company leverages its extensive expertise to bring forward new treatments that address significant medical needs.

Theravance Biopharma, Inc. also holds several registered trademarks, including THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo. Additionally, YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Other trademarks and service marks mentioned are the property of their respective owners.